华熙生物董事长赵燕：厚植合成生物平台，深耕衰老干预核心物质创新

Core Insights - The company is actively adjusting its operations and organizational structure to enhance its long-term competitiveness through technological innovation, focusing on synthetic biology as a core strategic direction [1][2][4] - The company has seen a profit growth of 55.63% year-on-year in Q3 2025, indicating the effectiveness of its reform measures [2] - The company aims to build a comprehensive ecosystem for its C-end business, which is crucial for validating technological innovations and meeting consumer needs [3][4] Group 1: Strategic Adjustments and Financial Performance - The company has implemented strategic adjustments that have led to a profit growth of 55.63% in Q3 2025, with a net profit of 0.32 billion and revenue of 9.03 billion [2] - The adjustments have resulted in a decrease in sales expense ratio to 34.26%, the lowest in five years, demonstrating effective cost control [3] - The company is focusing on C-end business as a key area for adjustment, emphasizing the need to understand consumer demands for resource allocation [2][3] Group 2: Research and Development Focus - The company is concentrating on glycoscience and cell biology, aiming to provide systematic solutions for delaying aging [4][5] - The synthetic biology system is supported by two core platforms: a biocatalyst library and a pilot transformation platform, which facilitate rapid development and industrialization of new molecules [5][6] - The company has developed a comprehensive research and transformation platform that integrates scientific research, pilot verification, and industrial application [4][5] Group 3: Pilot Platform and AI Integration - The pilot platform is a critical infrastructure for validating and scaling new materials, enabling the transition from laboratory research to market-ready products [7][8] - The company has invested in a pilot transformation platform in Tianjin, equipped with fermentation systems and production lines to support the scaling of biomanufacturing [7][8] - The integration of AI is aimed at enhancing the efficiency of the pilot platform, although the primary role remains with the scientific and engineering systems [7][9] Group 4: Future Directions and Industry Impact - The company plans to deepen its "pilot foundation, AI efficiency" model to solidify its position in the biomanufacturing sector [9] - The open and shared mechanism of the pilot platform is becoming a vital part of China's technological innovation system, supporting both the company's growth and the broader industry ecosystem [8][9] - The company aims to create an open, efficient, and sustainable synthetic biology innovation platform to drive future growth [6][9]